Do Wall Street Analysts Like Bristol-Myers Squibb Stock?

With a market cap of around $119 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines across areas such as oncology, immunology, cardiovascular disease, and neuroscience. It provides a broad portfolio of treatments for serious conditions including cancer, multiple sclerosis, and heart disease.

Shares of the Princeton, New Jersey-based company have underperformed the broader market over the past 52 weeks. BMY stock has increased 20.2% over this time frame, while the broader S&P 500 Index ($SPX) has gained 29.1%. However, the stock has risen 8% on a YTD basis, outpacing SPX's 4.3% return.